

Sprint Bioscience participates in a delegation trip to Washington DC

Sprint Bioscience is part of a delegation visiting Washington DC in the USA on March 11–14, 2024. The delegation is led by Sweden's Minister of Health Care, Ms. Acko Ankarberg Johansson.

"We are proud and honored to have been invited to participate in this journey. It is a recognition of our company and research. We will take the opportunity to meet previous contacts when we are on site, but also hope to make new valuable contacts during the trip," says Johan Emilsson, CEO of Sprint Bioscience.

It is on the occasion of the signing of an agreement between Sweden and the USA to strengthen bilateral cooperation around cancer research, development, innovation and implementation that the minister is visiting Washington DC. The delegation will, among other things, visit the oncology center at Johns Hopkins Hospital, and meet several important American key opinion leaders in the field of cancer. The aim is to promote cooperation and contacts between the USA and Sweden, particularly in the field of cancer. The Swecare Foundation, the Swedish Ministry of Health and Social Affairs and the Swedish Embassy organize the program in Washington DC.

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost:johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

Press Release
08 March 2024 14:30:00 CET



Image Attachments

[Johan Emilsson CEO Sprint Bioscience](#)

Attachments

[Sprint Bioscience participates in a delegation trip to Washington DC](#)